Status In progress
Process STA

Provisional Schedule

Expected publication 31 January 2018

Project Team

Project lead Thomas Feist

Email enquiries


Key events during the development of the guidance:

Date Update
02 November 2017 Committee meeting: 4
28 September 2017 - 19 October 2017 Appraisal consultation: 2
01 March 2017 The committee met to discuss ibrutinib for treating relapsed or refractory mantle cell lymphoma on 15 November 2016. The provisional/draft recommendation that the committee has made requires that the Institute conducts further work before the documentation can be issued. This is to ensure that the recommendation can be implemented once the guidance has been published. We will notify you in due course when we are ready to issue documentation
15 November 2016 Committee meeting: 3 closed
20 September 2016 Committee meeting: 2
18 August 2016 - 09 September 2016 Appraisal consultation
17 February 2016 Invitation to participate
16 December 2015 Draft scope documents
April 2015

As the phase 3 trial for this indication has not yet reported out, the company has requested that this STA is rescheduled so that these data can be included in the appraisal. As it is important that the most robust evidence available is considered by the appraisal committee, we have agreed to this request. It is anticipated that the appraisal will now begin during early February 2016.

For further information on how we develop guidance, please see our page about NICE technology appraisal guidance